JEMPERLI has demonstrated clinically meaningful efficacy1

JEMPERLI has demonstrated responses in patients (n=71) with recurrent or advanced dMMR endometrial cancer who progressed on or after a platinum-based regimen.1

Icon: Objective Response Rate Chart
Chart: Response Rate Chart
Icon: 42.3 percent overall response rate, 95 percent CI (30.6, 54.6)
Chart: 12.7 percent CR, 29.6 percent PR
  • Overall response rates in patients based on lines of prior therapy2:
    • 42.9% (n=18) in those who received 1 prior line [95% CI (27.7, 59.0)]
    • 41.4% (n=12) in those who received ≥2 prior lines [95% CI (23.5, 61.1)]
    • Due to small sample sizes and wide confidence intervals, results should be interpreted with caution
  • Responses with JEMPERLI were seen across recurrent or advanced endometrial cancer histologies, including serous, squamous, undifferentiated, and mixed carcinoma1

JEMPERLI has demonstrated a lasting response1,3

Primary endpoint: Duration of response1

  • With a median of 14.1 months of follow-up, the median duration of response had not been reached1†
  • 93.3% of responding patients demonstrated a duration of response ≥6 months1

Measured from time of first response.

Graph: JEMPERLI Response

BICR=blinded independent centralized review; RECIST v1.1=Response Evaluation Criteria in Solid Tumors version 1.1.

§Patients were permitted to remain on treatment after progression if they were considered to be benefiting from treatment. CT scans after treatment discontinuation were used to monitor disease for follow-up. All assessments are based on BICR per RECIST v1.1.

||These responses are based on a median duration of follow-up of 11.2 months.

Icon: JEMPERLI Trial

Explore the pivotal trial

Icon: JEMPERLI Safety

Learn about the safety and
tolerability profile of JEMPERLI.

Icon: JEMPERLI Dosing and Administration

Find out how to dose and
administer JEMPERLI.